TRMEDO Stock Overview
Produces and supplies alpha-particle emitters for cancer therapy in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Thor Medical ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 1.08 |
| 52 Week High | NOK 0 |
| 52 Week Low | NOK 0 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -23.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRMEDO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | n/a | -17.9% | 8.8% |
Return vs Industry: Insufficient data to determine how TRMEDO performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how TRMEDO performed against the UK Market.
Price Volatility
| TRMEDO volatility | |
|---|---|
| TRMEDO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: TRMEDO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TRMEDO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 2 | Jasper Kurth | www.thormedical.no |
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.
Thor Medical ASA Fundamentals Summary
| TRMEDO fundamental statistics | |
|---|---|
| Market cap | NOK 238.15m |
| Earnings (TTM) | -NOK 5.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-42.8x
P/E RatioIs TRMEDO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRMEDO income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 5.56m |
| Earnings | -NOK 5.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TRMEDO perform over the long term?
See historical performance and comparison